Compare Johnson & Johnson (JNJ) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Synchrony Financial — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Synchrony Financial trades at $72.8 (market cap $23.99B). The key difference: Johnson & Johnson is far larger — about 25.8× Synchrony Financial's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Synchrony Financial for 29 Days on average.
| JNJ | SYF | |
|---|---|---|
Market Cap | $618.09B | $23.99B |
Volume | 6,050,983 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $278.43 | $88.47 |
52-Week Low | $186.00 | $63.78 |
Typical Hold Time | 129 Days | 29 Days |
Enterprise Value | $646.37B | $24.23B |
Dividend Yield | 2.09% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Synchrony Financial (SYF) trades at $73.72, up 2.49% with strong technical support at $72 and resistance at $75. The stock shows compelling value with a P/E of 7.56 and ROE of 22.23%, supported by three consecutive earnings beats. Recent partnerships with OpenAI and Vetspire highlight strategic growth initiatives in AI-driven commerce and veterinary financing expansion.
SYF presents an attractive investment case with undervalued fundamentals and positive analyst sentiment, though technical indicators show mixed signals with RSI suggesting potential overbought conditions. Key risks include consumer credit quality concerns and competitive pressures in the financial services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
